Diana Keim is the VP of Annual Philanthropy at City of Hope, a world-renowned cancer and diabetes research and treatment organization in Duarte, CA. Diana is a seasoned philanthropy leader and professional with over 25 years of experience in the non-profit sector, with expertise in all fundraising channels. She is skilled in developing strategies to reinvigorate programs, using innovation and data-driven metrics. Her most recent promotion expanded her role to oversee the Corporate and Community Philanthropy and Engagement groups which has allowed her to leverage her ability to cultivate of relationships across entire organization for stronger work collaborations and partnerships for ultimate enterprise success.
Q:
Why is it important for corporations and industry groups to support a comprehensive cancer center like City of Hope?
A:
Partnerships often reside between similar organizations, but City of Hope looks at the potential of corporate partnership through a broader lens because it’s part of our history. Rewinding back to our roots in 1913, it was a volunteer group of workers and business leaders from the garment industry who created City of Hope on 10 acres of land in the California sun. Their mission was to bring hope and healing to people suffering with tuberculosis, one of the most pressing health challenges of the time.
Today, that singular vision of a philanthropic force to fight cancer, diabetes and other serious illnesses remains strong. More than 25,000 business leaders and corporate volunteers across the country are raising tens of millions of dollars each year for patient care and research. This support is vital because philanthropy allows us to help more people faster. Speed is an imperative here. We know our patients can’t afford to wait.
As one of only 51 comprehensive cancer centers in the nation, we’re setting the gold standard of care. Each year, more than 100 million people benefit from discoveries made at City of Hope. Synthetic human insulin was developed through our research, and we’ve pioneered the technology behind four of the top cancer drugs. This kind of global impact would not be possible without philanthropy and the investment of our corporate partners and industry volunteers.
A vision as ambitious as curing cancer requires the support of bold and like-minded partners to make it a reality. That’s why we are so grateful to all the forward-thinking industry leaders who invest so significantly in our mission.
